Sequence analysis of BRCA1 and BRCA2: Correlation of mutations with family history and ovarian cancer risk

Journal of Clinical Oncology

Volumn 16, Issue 7, 1998, Pages 2417-2425

  Frank, Thomas S ^a   Manley, Susan A ^b   Olopade, Olufunmilayo I ^b   Cummings, Shelly ^b   Garber, Judy E ^b   Bernhardt, Barbara ^b   Antman, Karen ^b   Russo, Donna ^b   Wood, Marie E ^b   Mullineau, Lisa ^b   Isaacs, Claudine ^b   Peshkin, Beth ^b   Buys, Saundra ^b   Venne, Vicki ^b   Rowley, Peter T ^b   Loader, Starlene ^b   Offit, Kenneth ^b   Robson, Mark ^b   Hampel, Heather ^b   Brener, Dara ^b   Winer, Eric P ^b   Clark, Shelly ^b   Weber, Barbara ^b   Strong, Louise C ^b   Rieger, Paula ^b   McClure, Melody ^b   Ward, Brian E ^b   Shattuck Eidens, Donna ^b   Oliphant, Arnold ^b   Skolnick, Mark H ^b   Thomas, Alun ^b   more..

^a Myriad Genetic Laboratories   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MODEL; ONCOGENE; OVARY CANCER; PATIENT SELECTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 0031832541     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.7.2417     Document Type: Article

References (36)

1. Claus EB, Schildkraut JM, Thompson WD, et al: The genetic attributable risk of breast and ovarian cancer. Cancer 77:2318-2324, 1996
2. Easton DF, Ford D, Bishop DT, et al: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 56:265-271, 1995
3. Easton DF, Bishop DT, Ford D, et al: Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. Am J Hum Genet 52:678-701, 1993
4. Wooster R, Bignell G, Lancaster J, et al: Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792, 1995
5. Couch FJ, DeShano ML, Blackwood MA, et al: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336:1409-1415, 1997
6. Serova OM, Mazoyer S, Puget N, et al: Mutations in BRCA1 and BRCA2 in breast cancer families: Are there more breast cancer-susceptibility genes? Am J Hum Genet 60:486-495, 1997
7. Tavtigian SV, Simard J, Rommens J, et al: The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 12:333-337, 1996
8. Krainer M, Silva-Arrieta S, Fitzgerald MG, et al: Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med 336:1416-1421, 1997
9. Stoppa-Lyonnet D, Laurent-Puig P, Essioux L, et al: BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet 60:1021-1030, 1997
10. Shattuck-Eidens D, Oliphant A, McClure M, et al: BRCA1 sequence analysis in women at high risk for susceptibility mutations: Risk factor analysis and implications for genetic testing. JAMA 278:1242-1250, 1997
11. Beaudet AL, Tsui LC: A suggested nomenclature for designating mutations. Hum Mut 2:245-248, 1993
12. Friedman LS, Ostermeyer EA, Szabo CI, et al: Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 8:399-404, 1994
13. Mazoyer S, Dunning AM, Serova O, et al: A polymorphic stop codon in BRCA2. Nat Genet 14:253-254, 1996
14. Wu LC, Wang ZW, Tsan JT, et al: Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 14:430-440, 1996
15. Miki Y, Swensen J, Shattuck-Eidens D, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71, 1994
16. Breast Cancer Information Core: http://www.nhgri.nih.gov/ Intramural_research/Lab_transfer/BIC, 1997
17. Aitkin M, Anderson D, Francis B, et al: Statistical Modelling in glim. Oxford, United Kingdom, Oxford University Press, 1989
18. Tessaro I, Borstelmann N, Regan K, et al: Genetic testing for susceptibility to breast cancer: Findings from women's focus groups. J Womens Health 6:317-327, 1997
19. Narod SA, Ford D, Devilee P, et al: An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet 56:254-264, 1995
20. Yancik R: Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71:517-523, 1993
21. Breast Cancer Facts and Figures 1996. Atlanta, GA, American Cancer Society, 1995, p 3
22. Phelan CM, Lancaster JM, Tonin P, et al: Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 13:120-122, 1996
23. Chapman MS, Verma IM: Transcriptional activation by BRCA1. Nature 382:678-679, 1996
24. Milner J, Ponder B, Hughes-Davies L, et al: Transcriptional activation functions in BRCA2. Nature 386:772-773, 1997
25. Berchuck A, Cirisano F, Lancaster JM, et al: Role of BRCA1 mutation screening in the management of familial ovarian cancer. Am J Obstet Gynecol 175:738-746, 1996
26. Gayther SA, Warren W, Mazoyer S, et al: Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 11:428-433, 1995
27. Burke W, Daly M, Garber J, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277:997-1003, 1997
28. NIH Consensus Development Panel on Ovarian Cancer: Ovarian cancer. Screening, treatment and follow-up. JAMA 273:491-497, 1995
29. Ford D, Easton DF, Bishop DT, et al: Risks of cancer in BRCA1-mutation carriers. Lancet 343:692-695, 1994
30. Struewing JP, Hartge P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408, 1997
31. Easton DF, Steele L, Fields P, et al: Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 61:120-128, 1997
32. Tonin P, Weber B, Offit K, et al: Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 2:1179-1183, 1996
33. Robson ME, Offit K: New BRCA2 mutation in an Ashkenazi Jewish family with breast and ovarian cancer. Lancet 350:117-118, 1997
34. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. J Clin Oncol 14:1730-1736, 1996
35. Vasen HFA, Mecklin J-P, Meera Khan P, et al: The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 34:424-425, 1991
36. Wijnen J, Meera Khan P, Vasen H, et al: Hereditary non-polyposis colorectal cancer families not complying with the Amsterdam criteria show extremely low frequency of mismatch-repair-gene mutations. Am J Hum Genet 61:329-335, 1997